Who is this protocol a good fit for?

Anyone considering Semax who wants the honest evidence before discussing it with a clinician. Readers researching nootropic peptides who have seen stroke-recovery or BDNF claims. Readers comparing Russian-registered pharmaceuticals to FDA-approved or purely preclinical peptides

← Home / Peptides / YourProtocol / Semax: Evidence, Legal Status, and Safety

Peptides Peptides

Semax: Evidence, Legal Status, and Safety

Semax is a synthetic nootropic peptide developed in Russia that raises BDNF (brain-derived neurotrophic factor) and has real published human trial data, including a controlled stroke-recovery study, unlike most research peptides. But that evidence base is Russian, has not been replicated in Western randomized trials, and Semax has no FDA approval or legal marketing pathway for any use in the US.

🧪

YourProtocol

YourProtocol Research

In-house · Synthesized from the cited primary sources

Daily time

5 min

Difficulty

Beginner

Sources

What the evidence says

What it is

Understand what's actually being sold

A synthetic heptapeptide derived from ACTH(4-10), developed at the Institute of Molecular Genetics, Russian Academy of Sciences; registered as a pharmaceutical (intranasal drops) in Russia and Ukraine since the 1990s for stroke recovery, optic nerve disease, and cognitive complaints.

Semax is not a general wellness supplement; it was developed and registered as a specific-indication pharmaceutical in specific countries.

Gusev et al., 2018 (PMID 29798983)

For this step

No product needed

Evidence tier: B

See what the human evidence actually shows

A controlled trial of 110 ischemic-stroke patients found intranasal Semax raised plasma BDNF and was associated with faster motor-function recovery and better Barthel Index scores. A separate acute-stroke RCT is referenced in some third-party summaries but could not be independently confirmed against a PubMed or DOI record; it is not cited here as settled.

Real controlled human trial data puts Semax ahead of most research peptides, but a single, non-replicated, non-Western trial is not the same as an established evidence base.

Gusev et al., 2018 (PMID 29798983)

For this step

No product needed

The honest caveat

Know the limits of this evidence

This entire evidence base is Russian, published mostly in Russian-language journals, and has not been replicated in a large Western randomized trial. Treat the stroke-recovery finding as real but not internationally confirmed.

Non-replication in independent, Western trials is a meaningful evidence gap, not a technicality.

Gusev et al., 2018 (PMID 29798983)

For this step

No product needed

Legal status

Know where it actually stands

Not FDA-approved for any use in the US; no US prescription or compounding pathway exists; sold in the US as an unregulated research chemical.

Registration as a pharmaceutical in Russia and Ukraine does not extend to any legal status in the US.

Research synthesis, 2026

For this step

No product needed

Safety

Know the real risk

Reported intranasal doses in Russian trials ranged roughly 600mcg to 12mg per day for up to 10 days without reported adverse events in that literature. No independent US safety review exists.

A safety record inside one country's trial literature is not the same as an independent regulatory safety review.

Gusev et al., 2018 (PMID 29798983)

For this step

No product needed

What it is

Semax is a synthetic heptapeptide derived from ACTH(4-10), developed at the Institute of Molecular Genetics, Russian Academy of Sciences, and registered as a pharmaceutical (intranasal drops) in Russia and Ukraine since the 1990s for stroke recovery, optic nerve disease, and cognitive complaints. This page reports the honest evidence tier, legal status, and safety picture; it does not describe how to use it.

Why it works▼

A controlled trial of 110 ischemic-stroke patients found intranasal Semax raised plasma BDNF and was associated with faster motor-function recovery and better Barthel Index scores. A second randomized, placebo-controlled acute-stroke trial has been referenced in third-party research summaries, but its exact citation could not be independently confirmed against a PubMed or DOI record in this research pass, so it is not cited here as settled evidence. This entire evidence base is Russian, published mostly in Russian-language journals, and has not been replicated in a large Western randomized trial; the stroke-recovery finding should be treated as real but not internationally confirmed.

The evidence

Sources 1

Primary sources behind this page, cited straight to the source: peer-reviewed papers and reporting. Select any to view it here.

Semax stroke-recovery and BDNF trial

Paper · 2018 (PMID 29798983)

Source viewer

Loading the first source…

Is this for you?

Good fit if

Anyone considering Semax who wants the honest evidence before discussing it with a clinician
Readers researching nootropic peptides who have seen stroke-recovery or BDNF claims
Readers comparing Russian-registered pharmaceuticals to FDA-approved or purely preclinical peptides

Cautions

Evidence base is Russian, published mostly in Russian-language journals, and not independently replicated in a Western randomized trial
A second, frequently-cited acute-stroke RCT could not be independently confirmed against a PubMed or DOI record in this research pass and is not cited here as settled
Not FDA-approved for any use in the US; sold in the US as an unregulated research chemical
Educational only, not medical advice

Common questions

Does Semax actually work?▾

There is real controlled human trial data: a study of 110 ischemic-stroke patients found intranasal Semax raised BDNF and was linked to faster motor-function recovery. But that evidence is Russian, published mostly in Russian-language journals, and has not been replicated in a Western randomized trial.

Is Semax legal in the US?▾

No. It is not FDA-approved for any use in the US, and there is no US prescription or compounding pathway. It is registered as a pharmaceutical in Russia and Ukraine, which does not extend to the US, where it is sold as an unregulated research chemical.

Is the Semax stroke evidence settled science?▾

The BDNF and motor-recovery trial (Gusev et al., 2018, PMID 29798983) is real and controlled, but it is a single, non-Western study. A second acute-stroke RCT referenced in some third-party summaries could not be independently confirmed in this research pass, so it is not treated as settled here.

Get the next protocol first

New expert protocols and evidence updates, cited to the source. No spam; unsubscribe anytime.

Not medical advice. This page is for education only and is not a substitute for professional medical care. Consult a qualified clinician before changing your health routine.
Editorial disclosure. This protocol is written and fact-checked by the YourProtocol editorial team directly from the primary sources cited below; it is not written or reviewed by any outside expert.

Semax: Evidence, Legal Status, and Safety

Read the evidence

Read it